Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: irinotecan
Drug: Carboplatin
Drug: sunitinib

First Posted Date: 2008-06-11

Last Posted Date: 2021-11-22

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 37

Registration Number: NCT00695292

Locations: 🇺🇸
Oncology Hematology Care, Cincinnati, Ohio, United States
🇺🇸
Florida Hospital Cancer Insitute, Orlando, Florida, United States
🇺🇸
Northeast Georgia Medical Center, Gainesville, Georgia, United States

and more 7 locations

Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

Phase 2

Conditions: Head and Neck Cancer

First Posted Date: 2008-06-05

Last Posted Date: 2009-06-29

Lead Sponsor: National Cancer Centre, Singapore

Target Recruit Count: 35

Registration Number: NCT00690872

Locations: 🇸🇬
National Cancer Centre - Singapore, Singapore, Singapore

Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Carboplatin
Drug: Bevacizumab
Drug: Paclitaxel

First Posted Date: 2008-06-05

Last Posted Date: 2016-09-22

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 46

Registration Number: NCT00691379

Locations: 🇬🇷
University General Hospital of Alexandroupolis, Alexandroupolis, Greece
🇬🇷
"IASO" General Hospital of Athens, 1st Dep of Medical Oncology, Athens, Greece
🇬🇷
"Laikon" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece

and more 8 locations

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

Phase 2

Completed

Conditions: Uterine Carcinosarcoma

Interventions: Drug: paclitaxel
Drug: carboplatin
Drug: BSI-201 (Iniparib)

First Posted Date: 2008-06-02

Last Posted Date: 2012-08-07

Lead Sponsor: Sanofi

Target Recruit Count: 22

Registration Number: NCT00687687

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer

Phase 3

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin
Drug: Etoposide
Radiation: Thoracic Radiation Therapy (TRT)
Drug: Vinorelbine
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2008-05-30

Last Posted Date: 2016-06-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 598

Registration Number: NCT00686959

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer
Non Small Cell Lung Cancer

Interventions: Drug: vandetanib induction
Drug: Docetaxel
Drug: Carboplatin
Drug: Placebo
Drug: Vandetanib maintenance

First Posted Date: 2008-05-30

Last Posted Date: 2018-05-30

Lead Sponsor: PrECOG, LLC.

Target Recruit Count: 162

Registration Number: NCT00687297

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Ocean Medical Center, Brick, New Jersey, United States

and more 27 locations

Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy

Active, not recruiting

Conditions: Brain and Central Nervous System Tumors
Cognitive/Functional Effects
Long-term Effects Secondary to Cancer Therapy in Children
Ototoxicity

First Posted Date: 2008-05-23

Last Posted Date: 2013-09-20

Lead Sponsor: Children's Cancer and Leukaemia Group

Target Recruit Count: 50

Registration Number: NCT00683319

Locations: 🇬🇧
Royal Manchester Children's Hospital, Manchester, England, United Kingdom
🇬🇧
Great Ormond Street Hospital for Children, London, England, United Kingdom
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom

and more 7 locations

Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: bevacizumab
Drug: carboplatin
Drug: nab-paclitaxel
Procedure: Surgery
Drug: Adjuvant chemotherapy

First Posted Date: 2008-05-09

Last Posted Date: 2018-07-24

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Target Recruit Count: 33

Registration Number: NCT00675259

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: Docetaxel
Radiation: radiation therapy

First Posted Date: 2008-04-22

Last Posted Date: 2012-09-07

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 63

Registration Number: NCT00664105

Locations: 🇺🇸
Erlanger Health System, Chattanooga, Tennessee, United States
🇺🇸
Lehigh Valley Hospital - John & Dorothy Morgan Cancer Center, Allentown, Pennsylvania, United States
🇺🇸
The West Clinic, PC, Memphis, Tennessee, United States

and more 12 locations

ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: ASA404
Drug: carboplatin
Drug: Paclitaxel

First Posted Date: 2008-04-21

Last Posted Date: 2020-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1285

Registration Number: NCT00662597

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Sinai Hospital of Baltimore - The Alvin & Lois Lapidus Cancer Institute, Baltimore, Maryland, United States
🇺🇸
Arlington Cancer Center, Arlington, Texas, United States

and more 98 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy